|
1
|
Raida M, Clement JH, Leek RD, Ameri K,
Bicknell R, Niederwieser D and Harris AL: Bone morphogenetic
protein 2 (BMP-2) and induction of tumor angiogenesis. J Cancer Res
Clin Oncol. 131:741–750. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lian WJ, Liu G, Liu YJ, Zhao ZW, Yi T and
Zhou HY: Downregulation of BMP6 enhances cell proliferation and
chemoresistance via activation of the ERK signaling pathway in
breast cancer. Oncol Rep. 30:193–200. 2013.PubMed/NCBI
|
|
3
|
Buijs JT, Petersen M, van der Horst G and
van der Pluijm G: Bone morphogenetic proteins and its receptors;
therapeutic targets in cancer progression and bone metastasis? Curr
Pharm Des. 16:1291–1300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Boeuf S, Bovée JV, Lehner B, van den Akker
B, van Ruler M, Cleton-Jansen AM and Richter W: BMP and TGFbeta
pathways in human central chondrosarcoma: Enhanced endoglin and
Smad 1 signaling in high grade tumors. BMC Cancer. 12:4882012.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ye L, Mason MD and Jiang WG: Bone
morphogenetic protein and bone metastasis, implication and
therapeutic potential. Front Biosci (Landmark Ed). 16:865–897.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Guo D, Huang J and Gong J: Bone
morphogenetic protein 4 (BMP4) is required for migration and
invasion of breast cancer. Mol Cell Biochem. 363:179–190. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lim J, Tu X, Choi K, Akiyama H, Mishina Y
and Long F: BMP-Smad4 signaling is required for precartilaginous
mesenchymal condensation independent of Sox9 in the mouse. Dev
Biol. 400:132–138. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Olsen OE, Wader KF, Misund K, Våtsveen TK,
Rø TB, Mylin AK, Turesson I, Størdal BF, Moen SH, Standal T, et al:
Bone morphogenetic protein-9 suppresses growth of myeloma cells by
signaling through ALK2 but is inhibited by endoglin. Blood Cancer
J. 4:e1962014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lei R, Zhang K, Liu K, Shao X, Ding Z,
Wang F, Hong Y, Zhu M and Li H and Li H: Transferrin receptor
facilitates TGF-β and BMP signaling activation to control
craniofacial morphogenesis. Cell Death Dis. 7:e22822016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Brederlau A, Faigle R, Elmi M, Zarebski A,
Sjöberg S, Fujii M, Miyazono K and Funa K: The bone morphogenetic
protein type Ib receptor is a major mediator of glial
differentiation and cell survival in adult hippocampal progenitor
cell culture. Mol Biol Cell. 15:3863–3875. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bokobza SM, Ye L, Kynaston HE, Mansel RE
and Jiang WG: Reduced expression of BMPR-IB correlates with poor
prognosis and increased proliferation of breast cancer cells.
Cancer Genomics Proteomics. 6:101–108. 2009.PubMed/NCBI
|
|
12
|
Alsamarah A, LaCuran AE, Oelschlaeger P,
Hao J and Luo Y: Uncovering molecular bases underlying bone
morphogenetic protein receptor inhibitor selectivity. PLoS One.
10:e01322212015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Herrera-Esparza R, Pacheco-Tovar D,
Bollain-Y-Goytia JJ, Del Muro F Torres, Ramírez-Sandoval R,
Pacheco-Tovar MG, Castañeda-Ureña M and Avalos-Díaz E: An activin
receptor IA/activin-like kinase-2 (R206H) mutation in
fibrodysplasia ossificans progressiva. Case Rep Genet.
2013:2603712013.PubMed/NCBI
|
|
14
|
Joziasse IC, Smith KA, Chocron S, van
Dinther M, Guryev V, van de Smagt JJ, Cuppen E, Ten Dijke P, Mulder
BJ, Maslen CL, et al: ALK2 mutation in a patient with Down's
syndrome and a congenital heart defect. Eur J Hum Genet.
19:389–393. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Song T, Wang W, Xu J, Zhao D, Dong Q, Li
L, Yang X, Duan X, Liang Y, Xiao Y, et al: Fibroblast growth factor
2 inhibits bone morphogenetic protein 9-induced osteogenic
differentiation of mesenchymal stem cells by repressing Smads
signaling and subsequently reducing Smads dependent up-regulation
of ALK1 and ALK2. Int J Biochem Cell Biol. 45:1639–1646. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chakkalakal SA, Zhang D, Culbert AL,
Convente MR, Caron RJ, Wright AC, Maidment AD, Kaplan FS and Shore
EM: An Acvr1 R206H knock-in mouse has fibrodysplasia ossificans
progressiva. J Bone Miner Res. 27:1746–1756. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Thomas PS, Sridurongrit S, Ruiz-Lozano P
and Kaartinen V: Deficient signaling via Alk2 (Acvr1) leads to
bicuspid aortic valve development. PLoS One. 7:e355392012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Herrera B, van Dinther M, Ten Dijke P and
Inman GJ: Autocrine bone morphogenetic protein-9 signals through
activin receptor-like kinase-2/Smad1/Smad4 to promote ovarian
cancer cell proliferation. Cancer Res. 69:9254–9262. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tsai CL, Tsai CN, Lin CY, Chen HW, Lee YS,
Chao A, Wang TH, Wang HS and Lai CH: Secreted stress-induced
phosphoprotein 1 activates the ALK2-SMAD signaling pathways and
promotes cell proliferation of ovarian cancer cells. Cell Rep.
2:283–293. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Romero D, Terzic A, Conley BA, Craft CS,
Jovanovic B, Bergan RC and Vary CP: Endoglin phosphorylation by
ALK2 contributes to the regulation of prostate cancer cell
migration. Carcinogenesis. 31:359–366. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang K, Feng H, Ren W, Sun X, Luo J, Tang
M, Zhou L, Weng Y, He TC and Zhang Y: BMP9 inhibits the
proliferation and invasiveness of breast cancer cells MDA-MB-231. J
Cancer Res Clin Oncol. 137:1687–1696. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Langenfeld E, Hong CC, Lanke G and
Langenfeld J: Bone morphogenetic protein type I receptor
antagonists decrease growth and induce cell death of lung cancer
cell lines. PLoS One. 8:e612562013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Na YR, Seok SH, Kim DJ, Han JH, Kim TH,
Jung H, Lee BH and Park JH: Bone morphogenetic protein 7 induces
mesenchymal-to-epithelial transition in melanoma cells, leading to
inhibition of metastasis. Cancer Sci. 100:2218–2225. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Leask A, Denton CP and Abraham DJ:
Insights into the molecular mechanism of chronic fibrosis: the role
of connective tissue growth factor in scleroderma. J Invest
Dermatol. 122:1–6. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cozzolino M, Biondi ML, Banfi E, Riser BL,
Mehmeti F, Cusi D and Gallieni M: CCN2 (CTGF) gene polymorphism is
a novel prognostic risk factor for cardiovascular outcomes in
hemodialysis patients. Blood Purif. 30:272–276. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kim GJ, Rhee H, Yoo JE, Ko JE, Lee JS, Kim
H, Choi JS and Park YN: Increased expression of CCN2, epithelial
membrane antigen, and fibroblast activation protein in
hepatocellular carcinoma with fibrous stroma showing aggressive
behavior. PLoS One. 9:e1050942014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lacle MM, van Diest PJ, Goldschmeding R,
van der Wall E and Nguyen TQ: Expression of connective tissue
growth factor in male breast cancer: clinicopathologic correlations
and prognostic value. PLoS One. 10:e01189572015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jacobson A and Cunningham JL: Connective
tissue growth factor in tumor pathogenesis. Fibrogenesis Tissue
Repair. 5:(Suppl 1). S82012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wazir U, Jiang WG, Sharma AK, Newbold RF
and Mokbel K: The mRNA expression of inhibitors of DNA binding-1
and −2 is associated with advanced tumour stage and adverse
clinical outcome in human breast cancer. Anticancer Res.
33:2179–2183. 2013.PubMed/NCBI
|
|
30
|
Clementi C, Tripurani SK, Large MJ, Edson
MA, Creighton CJ, Hawkins SM, Kovanci E, Kaartinen V, Lydon JP,
Pangas SA, et al: Activin-like kinase 2 functions in
peri-implantation uterine signaling in mice and humans. PLoS Genet.
9:e10038632013. View Article : Google Scholar : PubMed/NCBI
|
